American biotechnology company Moderna intends to set the price for a course of vaccine against coronavirus at the level of $50-60. Such rates will be in effect for the United States and other countries where there is a “high income”.
Reported by the Financial Times, citing sources. According to interlocutors of the edition, Moderna is likely to be forced to lose price because once the called numbers that are higher than the companies Pfizer and BioNTech. They concluded with the White house an agreement to sell up to 600 million doses of their respective vaccines COVID-19. However, their dose will cost just $19,5.
Earlier NEWS.ru reported that a strong immune response to the coronavirus recorded in all 45 patients participating in first-stage human trials of a vaccine against COVID-19. The drug created the American biotech company Moderna. In clinical trials patients received two doses of a potential vaccine, all volunteers developed antibodies.
